AUSTIN, Texas – One year of romosozumab (Evenity) followed by 1 year of denosumab (Prolia, Xgeva) was associated with improved bone mineral density (BMD) and lower fracture incidence compared with 2 ...

Romosozumab leads to a greater increase in bone mineral density (BMD) than teriparatide in postmenopausal women, with lower discontinuation rates and fewer cardiovascular events. Romosozumab and ...

The Endocrine Society updated its osteoporosis clinical practice guideline to include recommendations for romosozumab, noting that the monthly injection therapy is an “effective option” for ...

Latest guidelines on the treatment of osteoporosis have been released that include new recommendations for the use of romosozumab (Evenity, Amgen) in postmenopausal women with severe osteoporosis, but ...

Peter L. Salgo, MD: Based on all this, I know you said there were data. There were trials. I’ve gotten this written down. I’m not making this up. There’s the FRAME study, and there’s the ARCH study.